Αρχική World News Consensus on Conceptual Framework for Precision Cancer Medicine in Germany

Consensus on Conceptual Framework for Precision Cancer Medicine in Germany

In the August 2020 issue of the European Journal of Cancer, a group of German investigators reported on the formation of a working group entitled ‘Molecular Diagnostics and Therapy’ with support of the ‘German Cancer Aid’ (Deutsche Krebshilfe [DKH]). Through participation in two workshops supported by the DKH, delegates from the fourteen comprehensive cancer centres in Germany identified key topics essential to implement quality driven, harmonised and adaptable precision cancer medicine. The group aims to use a set of consensus statements as a basis for defining a collaborative strategy to sustain and further improve quality of precision cancer medicine in Germany.

The authors led by C. Benedikt Westphalen of the Department of Internal Medicine III, University Hospital, LMU Munich and Comprehensive Cancer Center in Munich and Sonja Loges of the University Comprehensive Cancer Center Hamburg who has recently transitioned to the University Hospital Mannheim and the German Cancer Research Center (DKFZ) report that precision cancer medicine in Germany is mainly practiced in academic institutions.

As of now, there are some initiatives to initiate national harmonisation, but these efforts are still uncoordinated. To facilitate exchange between academic centres and to develop a strategy for the future directions of precision cancer medicine in Germany, the ‘Molecular Diagnostics and Therapy’ task force was established within the DKH supported comprehensive cancer centres network.

Based on an online questionnaire, the task force defined challenges needed to be addressed for successful implementation of precision cancer medicine. During two workshops, these challenges were discussed by the working group members, who then defined the general framework for a consensus paper.

In total, nine statements covering various aspects of precision cancer medicine were drafted and distributed within the working group. By using a modified Delphi approach, these statements were refined within a stepwise procedure and consented by the working group members. The statements were assumed accepted, if there was an agreement by ≥80% of the participants.

The first consensus statement concerns benefit and limitations of comprehensive genomic profiling and the need for a proper education of physicians in precision cancer medicine.

In the second consensus statement, focus lays on cooperation among treating physicians and molecular pathologists to guarantee state-of-the-art molecular tumour profiling.

The need to reach harmonised reporting of genomic alterations across cancer centres is described in the third consensus statement.

The fourth consensus statement outlines, that clinical implications of genomic alterations should be consented by (molecular) pathologists and clinicians. Additional support can be provided by bioinformaticians and geneticists. This process should preferentially be realised in dedicated interdisciplinary molecular tumour boards. Development of an evidence framework is encouraged through prospective data collection, clinical-molecular registries and early clinical trials.

In the fifth consensus statement, a potential composition of molecular tumour boards with minimal requirements is outlined. According to the authors, a molecular tumour board should include a molecular pathologist, the treating oncologist, oncologists with expertise in different subspecialties and ideally a geneticist, a bioinformatician, as well as a specialist in molecular biology.

The need to ensure access to therapy is outlined in the sixth consensus statement. In this regard, the participants recognised that access to targeted therapy after identification of actionable molecular targets is currently not sufficient. One potential strategy to overcome this problem could be to concentrate precision cancer medicine at specialised centres to provide a rationale to payers to cover ‘off label’ treatment, as well as conducting clinical trials to offer treatment for rare genetic alterations through a network of participating centres.

The seventh consensus statement concerns structured and harmonised collection of patient data in clinico-genomic databases supported by adequate bioinformatics. This real world evidence approach could allow to evaluate the benefit from individualised treatment and to create learning systems.

In the eighth consensus statement, the participants argued that for ensuring high-quality diagnostics, comprehensive medical management and cost-effectiveness and to prevent repetitive diagnostic procedures, precision cancer medicine should preferably be concentrated at specialised centres which should lead a dialogue with payers to establish the reimbursement modalities for all aspects of precision cancer medicine.

In the ninth consensus statement, the participants recommended that extended molecular profiling should be a part of adequate counselling process by the treating oncologist, human geneticist and psycho-oncologist.

The authors concluded that these nine statements could constitute a framework for future collaborative efforts to further develop and expand precision cancer medicine within the comprehensive network to provide optimal care for cancer patients across Germany.

Reference

Westphalen BC, Bokemeyer C, Büttner R, et al. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’. European Journal of Cancer 2020; 135:1-7.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung Cancer, Breast Cancer, and Sarcoma

In the annual Research Round Up series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field...

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

The right combination for early detection

The upcoming Early Detection of Cancer Conference brings together experts from multiple disciplines to share ground breaking research and progress in the field. Here...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...